Top U.S. Defense Stocks to Watch According to Jefferies Analysis
Investing.com - Cantor Fitzgerald initiated coverage on CytomX Therapeutics (NASDAQ:CTMX) with an Overweight rating and a $6.00 price target on Monday. The company, currently trading at $1.98 with a market cap of $327 million, maintains strong financial health according to InvestingPro data, with a P/E ratio of 4.04 and analyst targets ranging from $3.50 to $8.00.
The research firm cited CytomX’s potential "shot at redemption" with its CX-2051 program, a masked epithelial cell adhesion molecule antibody-drug conjugate (EpCAM ADC) that shows promise in late-line colorectal cancer treatment. InvestingPro analysis reveals the company holds more cash than debt on its balance sheet, though it’s currently burning through cash rapidly - one of several key insights available in the comprehensive Pro Research Report.
Cantor Fitzgerald noted that late-line colorectal cancer represents a market with "low efficacy benchmarks and no good options," positioning CytomX’s candidate as a potential breakthrough in an underserved therapeutic area.
The firm acknowledged some investor skepticism reflected in the current stock price, which it considers reasonable given EpCAM’s "toxic history" including pancreatitis and liver enzyme elevations, along with the early stage of available clinical data.
An important phase 1 readout for CX-2051 is expected in the first quarter of 2026, which Cantor Fitzgerald believes could validate CytomX’s "first-in-class space with blockbuster potential" in colorectal cancer and possibly additional indications.
In other recent news, CytomX Therapeutics reported a decline in revenue and a significant miss on earnings per share (EPS) forecasts for Q2 2025. This financial update has raised concerns among investors, although the company remains focused on its innovative cancer treatments. Additionally, CytomX provided a safety update for its ongoing Phase 1 study of CX-2051, noting that dose expansion cohorts have been enrolled as planned. However, the company disclosed a patient death in the study, attributed to a treatment-related acute kidney injury in a patient with a complex medical history. The U.S. Food and Drug Administration was notified of this incident, adhering to regulatory requirements. In a separate development, Barclays initiated coverage on CytomX with an Overweight rating and a price target of $3.50, highlighting a positive risk-reward outlook for the company’s lead clinical program, CX-2051. These recent developments reflect both challenges and potential opportunities for CytomX Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.